Literature DB >> 18297714

Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection.

N Bouzgarrou1, E Hassen, E Schvoerer, F Stoll-Keller, O Bahri, S Gabbouj, I Cheikh, N Maamouri, N Mammi, H Saffar, A Trabelsi, H Triki, L Chouchane.   

Abstract

Hepatitis C virus (HCV) infection is the main cause of chronic liver disease throughout the world, and may progress to cirrhosis and hepatocellular carcinoma (HCC). Immunological factors, especially cytokines and some host genetic variations, rather than direct HCV action, seem to play an important role in the pathogenesis of HCV infection. Elevated levels of interleukin-18 (IL-18) were described previously for chronically (HCV)-infected patients. This study is aimed at investigating IL-18 promoter polymorphisms (-607C/A and -137G/C) in HCV-infected patients with different disease severities (chronic hepatitis C, liver cirrhosis and HCC) and establishing an association between these polymorphisms and IL-18 plasma concentration with the outcome of chronic HCV infection. The carriage of at least one C allele at position -607 (CC + CA) was associated with a higher risk of cirrhosis and HCC (P = 0.032). Compared with controls, HCV-infected patients had significantly higher levels of IL-18 (P = 0.0001) that correlate with disease severity (P = 0.01, P = 0.001, P = 0.0006, respectively). In conclusion, we supposed a possible implication of IL-18 promoter polymorphisms in the pathogenesis of chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297714     DOI: 10.1002/jmv.21079

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  17 in total

1.  Combined effect of pro- and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients.

Authors:  Nadia Bouzgarrou; Elham Hassen; Olfa Bahri; Sallouha Gabbouj; Nabil Ben Mami; Henda Triki; Lotfi Chouchane
Journal:  Hepatol Int       Date:  2011-02-08       Impact factor: 6.047

2.  Proapoptotic IL-18 in patients with chronic hepatitis C treated with pegylated interferon-alpha.

Authors:  He YingLi; Lin Shumei; Yang Qian; Chen Tianyan; Zhao Yingren; Chen Wei
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

Review 3.  Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.

Authors:  Mahmoud Fathy Dondeti; Eman Anwar El-Maadawy; Roba Mohamed Talaat
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 4.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

5.  Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis.

Authors:  Arpita Sharma; Anuradha Chakraborti; Ashim Das; Radha Krishan Dhiman; Yogesh Chawla
Journal:  Immunology       Date:  2008-11-24       Impact factor: 7.397

6.  Association between interleukin-18 gene promoter (- 607C/A and - 137G/C) polymorphisms and chronic hepatitis C virus infections: A meta-analysis.

Authors:  Yi Yang; Hao Liu
Journal:  Meta Gene       Date:  2015-05-22

7.  Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response.

Authors:  Stephan L Haas; Christel Weiss; Peter Bugert; Jutta Gundt; Heiko Witt; Manfred V Singer; Thomas Berg; Ulrich Böcker
Journal:  J Clin Immunol       Date:  2009-05-20       Impact factor: 8.542

Review 8.  Interleukin 18 gene promoter polymorphisms and susceptibility to chronic hepatitis B infection: a review study.

Authors:  Mahsa Motavaf; Saeid Safari; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2014-07-01       Impact factor: 0.660

9.  The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir.

Authors:  David F G Malone; Karolin Falconer; Ola Weiland; Johan K Sandberg
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240

10.  IL18 Gene Variants Influence the Susceptibility to Chagas Disease.

Authors:  Daniel A Leon Rodriguez; F David Carmona; Luis Eduardo Echeverría; Clara Isabel González; Javier Martin
Journal:  PLoS Negl Trop Dis       Date:  2016-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.